Ontology highlight
ABSTRACT: Introduction
Baricitinib is an oral Janus kinase (JAK)1/JAK2 inhibitor approved to treat rheumatoid arthritis (RA). This study aimed to investigate patients' characteristics, prescription patterns, effectiveness, and treatment persistence in patients receiving baricitinib in real-world practice in Spain.Methods
This retrospective longitudinal cohort study conducted in five rheumatology units included adults with RA initiating baricitinib (Sep-2017-May-19) with at least a 6-month-follow-up. Demographic/clinical characteristics, prescription patterns, and changes in disease activity and pain level were collected until treatment discontinuation/end of follow-up. Treatment persistence was estimated by Kaplan-Meier methods.Results
Data from 182 patients were included (me
SUBMITTER: Hernandez-Cruz B
PROVIDER: S-EPMC8964893 | biostudies-literature | 2022 Apr
REPOSITORIES: biostudies-literature